Nordic Pharma GmbH
Pharmaceutical Companies · München
Nordic Pharma GmbH is a pharmaceutical company based in München, Bavaria, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Nordic Pharma GmbH Address & Contact
Company profile
2005
Founded
400+
Employees
Nordic Pharma GmbH Overview
Nordic Pharma GmbH is the German subsidiary of the Nordic Pharma Group, a European specialty pharmaceutical company headquartered in Paris (France). Founded in 2005, Nordic Pharma has focused on the development and marketing of specialty therapeutics in selected therapeutic niches. These niches are often characterized by relatively low competition from generics, allowing the company to achieve unique market advantages. With a presence in more than 20 European countries and around 400 employees on the continent, Nordic Pharma ensures that innovative products reach the market quickly and efficiently. The branch in Munich is particularly important as it is responsible for the German-speaking market (Germany, Austria, Switzerland) and thus plays a significant role in regional healthcare delivery.
Field of Activity & Products
Nordic Pharma is active in several therapeutic areas in Germany, contributing to the creation of a diversified portfolio. In the field of gastroenterology, the company offers, among other things, valganciclovir formulations specifically developed for organ transplant recipients. These antiviral specialties are crucial for postoperative treatment regimens, as they significantly reduce the risk of viral infections. In the areas of rheumatology and orthopedics, Nordic Pharma distributes hyaluronic acid preparations used in intra-articular injections. These treatments are particularly prevalent for osteoarthritis, with a focus on gonarthrosis, or knee osteoarthritis. Continuing with its focus on specific niche markets, Nordic Pharma also serves the fields of dermatology and women's therapeutics. These are products that are often introduced to the German market through licensing agreements with international producers. Products are also offered that are already successful in other markets, which avoids the need for extensive clinical studies while promoting innovation in established therapeutic approaches.
Regulation & Strategy
The products of Nordic Pharma are carefully selected to ensure that they meet the specific requirements of European markets. Distribution primarily occurs through licensed products sourced from the Asia-Pacific region or other international markets. This strategic orientation allows the company to leverage the benefits of global innovations while also addressing local needs. All products are subject to strict regulatory requirements by the Federal Institute for Drugs and Medical Devices (BfArM) as well as the European Medicines Agency (EMA), ensuring the safety and efficacy standards of the products. Nordic Pharma is also a member of the Federal Association of Pharmaceutical Industry (BPI), which promotes networking with other players in the pharmaceutical industry and prepares the company for current developments in pharmaceutical policy and regulation. These memberships, along with ongoing market trend analysis, play a central role in the strategic orientation of the company. In a constantly changing healthcare environment, Nordic Pharma positions itself through an intelligent product strategy and strong regulatory understanding to remain competitive in the long term.
Regional Significance
The significance of Nordic Pharma GmbH extends beyond mere business figures and also includes its social impact on the Munich region and neighboring German-speaking countries. As an employer, Nordic Pharma not only offers numerous jobs but also actively engages in social and health-promoting programs that serve the welfare of the community. Furthermore, the company collaborates with local healthcare facilities to enable patients to receive the best possible treatment through access to innovative therapies. This responsibility underscores Nordic Pharma's commitment to exert a positive influence on society and sustainably improve the quality of life for people in the region.
Further information: Pharmaceutical companies in Bavaria or all pharmaceutical companies in Germany on Sanoliste.
```Frequently asked questions about Nordic Pharma GmbH
What does Nordic Pharma GmbH do?
Nordic Pharma GmbH hat sich als deutsches Tochterundernehmen the Nordic Group on Marketing and distribution fokussiert. Therapiegebiete are Gynäkologie, Rheumatologie and Onkologie. Antheen Herstellern offers sie Unterstützung an at Vermarktung and Regisrierung ihrer Arzneiprodukte.
More Pharmaceutical Companies in München
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.